Although it’s Mylan’s policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue.
Management details progress on complex scientific programs and commercial diversification; reaffirms 2018 guidance Company is built to last and positioned for growth HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
Mylan acquires global development and marketing rights from Prayog Labs Once approved, the product could potentially offer a fast-acting, non-addictive treatment for acute pain HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
Mylan acquires exclusive license to commercialize in Europe HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd.
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support marketing applications
HERTFORDSHIRE, England and PITTSBURGH , April 6, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billion aggregate principal amount of senior notes on March 28, 2018 , comprised of: $750 million aggregate
Mylan Announcement of Redemption of Notes HERTFORDSHIRE, England and PITTSBURGH – Mar. 29, 2018 – Today Mylan N.V. and Mylan Inc., an indirect wholly owned subsidiary of Mylan N.V., delivered notices to The Bank of New York Mellon, as trustee (the “Trustee”), notifying the Trustee of their
- Approval complements growing portfolio of cost-saving antiretroviral medications available to patients in the U.S., including recently announced Symfi Lo™ and Cimduo™ - All ARV regimens are being offered at a significant discount to the price of competing products to bring cost savings to the $20
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , March 27, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL), one of the world's leading pharmaceutical companies, and Biocon Ltd. (BSE code: 532523, NSE: BIOCON ), Asia's premier biopharmaceutical company, today announced that their
HERTFORDSHIRE, England and PITTSBURGH , March 21, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it will host an Investor Day on April 11, 2018 , in New York City . Mylan CEO Heather Bresch and the company's senior leadership team will showcase how Mylan is Built to Last